Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Damora Therapeutics, Inc. Common Stock (DMRA) Financials

Damora Therapeutics, Inc. Common Stock logo
$25.30 +0.44 (+1.77%)
As of 05/22/2026 04:00 PM Eastern
Compare
Annual Income Statements for Damora Therapeutics, Inc. Common Stock

Annual Income Statements for Damora Therapeutics, Inc. Common Stock

This table shows Damora Therapeutics, Inc. Common Stock's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -35 -53 -62 -38 -21 -210
Consolidated Net Income / (Loss)		 -37 -35 -52 -62 -38 -21 -210
Net Income / (Loss) Continuing Operations		 -34 -35 -52 -62 -38 -21 -210
Total Pre-Tax Income 		-37 -35 -52 -62 -38 -21 -210
Total Operating Income		 39 -34 -52 -61 -40 -22 -211
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 39 34 52 61 40 22 211
Selling, General & Admin Expense		 -2.45 9.01 14 13 13 10 9.69
Research & Development Expense		 -37 25 38 48 24 11 201
Restructuring Charge		 - - - 0.00 3.45 0.97 0.00
Total Other Income / (Expense), net		 2.46 -1.20 0.48 -0.42 1.56 0.86 1.08
Interest Expense		 - 0.00 -0.16 -0.72 -1.69 -0.84 -1.17
Interest & Investment Income		 - - 0.00 -0.07 0.00 0.00 0.00
Other Income / (Expense), net		 2.46 -1.20 0.32 -1.07 -0.13 0.02 -0.08
Income Tax Expense		 - - - - 0.00 0.04 0.05
Basic Earnings per Share		 ($161.82) ($7.62) ($2.05) ($2.43) ($36.08) ($18.53) $3.98
Weighted Average Basic Shares Outstanding		 259.97K 4.57M 25.26M 25.41M 1.06M 1.16M 1.36M
Diluted Earnings per Share		 ($161.82) ($7.62) ($2.05) ($2.43) ($36.08) ($18.53) $3.98
Weighted Average Diluted Shares Outstanding		 259.97K 4.57M 25.26M 25.41M 1.06M 1.16M 1.36M
Weighted Average Basic & Diluted Shares Outstanding		 259.97K 4.57M 25.26M 25.67M 27.11M 1.32M 60.30M
Cash Dividends to Common per Share		 - $0.00 $0.00 - - $0.00 $0.00

Quarterly Income Statements for Damora Therapeutics, Inc. Common Stock

This table shows Damora Therapeutics, Inc. Common Stock's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.95 -6.14 -5.53 -5.47 -3.42 -7.03 -2.33 -2.93 -3.12 -201 -28
Consolidated Net Income / (Loss)		 -8.14 -6.48 -5.48 -5.34 -3.88 -6.74 -2.53 -3.44 -3.13 -201 -28
Net Income / (Loss) Continuing Operations		 -8.14 -6.48 -5.48 -5.34 -3.88 -6.74 -2.53 -3.44 -3.13 -201 -28
Total Pre-Tax Income 		-8.14 -6.48 -5.48 -5.30 -3.88 -6.75 -2.53 -3.43 -3.13 -201 -28
Total Operating Income		 -8.58 -6.67 -5.74 -5.58 -3.84 -7.10 -2.60 -3.42 -3.16 -202 -31
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.58 6.67 5.74 5.58 3.84 7.10 2.60 3.42 3.16 202 31
Selling, General & Admin Expense		 3.30 3.18 3.28 2.78 2.75 1.70 1.92 1.96 1.74 4.07 7.03
Research & Development Expense		 2.55 2.77 2.46 1.83 1.09 5.40 0.68 1.47 1.42 198 24
Restructuring Charge		 2.73 - 0.00 0.97 0.00 - 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net		 0.45 0.20 0.26 0.28 -0.04 0.35 0.07 -0.01 0.02 1.00 3.07
Interest Expense		 -0.47 -0.34 -0.26 -0.21 -0.15 -0.23 -0.07 -0.05 -0.04 -1.00 -3.07
Interest & Investment Income		 - - - - - - 0.00 - - - 0.00
Other Income / (Expense), net		 -0.03 -0.14 0.01 0.07 -0.18 0.13 -0.01 -0.06 -0.02 0.00 0.00
Income Tax Expense		 0.00 - 0.00 0.04 0.01 -0.01 0.00 0.00 0.00 0.04 0.04
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.18 -0.33 0.05 0.13 -0.47 - -0.20 -0.51 -0.01 - 0.05
Basic Earnings per Share		 ($7.50) ($5.78) ($5.05) ($4.92) ($3.39) ($6.07) ($1.92) ($2.60) ($2.36) ($147.81) ($0.62)
Weighted Average Basic Shares Outstanding		 1.08M 1.06M 1.08M 1.08M 1.14M 1.16M 1.32M 1.32M 1.33M 1.36M 34.30M
Diluted Earnings per Share		 ($7.50) ($5.78) ($5.05) ($4.92) ($3.39) ($6.07) ($1.92) ($2.60) ($2.36) ($147.81) ($0.62)
Weighted Average Diluted Shares Outstanding		 1.08M 1.06M 1.08M 1.08M 1.14M 1.16M 1.32M 1.32M 1.33M 1.36M 34.30M
Weighted Average Basic & Diluted Shares Outstanding		 27.11M 27.11M 27.11M 27.13M 1.32M 1.32M 1.32M 1.32M 1.33M 60.30M 61.55M
Cash Dividends to Common per Share		 - - - - - - - - - - $0.00

Annual Cash Flow Statements for Damora Therapeutics, Inc. Common Stock

This table details how cash moves in and out of Damora Therapeutics, Inc. Common Stock's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -20 149 -100 -30 -12 -6.97 243
Net Cash From Operating Activities		 -19 -38 -52 -43 -37 -19 -6.73
Net Cash From Continuing Operating Activities		 -19 -38 -52 -43 -37 -19 -6.73
Net Income / (Loss) Continuing Operations		 -37 -35 -52 -62 -38 -21 -210
Consolidated Net Income / (Loss)		 -37 -35 -52 -62 -38 -21 -210
Depreciation Expense		 - 0.00 0.02 0.04 0.27 0.02 0.02
Amortization Expense		 0.11 0.19 1.49 0.57 0.13 0.23 0.01
Non-Cash Adjustments To Reconcile Net Income		 15 1.04 4.56 5.61 5.41 5.23 185
Changes in Operating Assets and Liabilities, net		 2.20 -4.59 -6.62 12 -4.37 -2.67 18
Net Cash From Investing Activities		 -0.33 0.00 -48 12 22 12 -17
Net Cash From Continuing Investing Activities		 -0.33 0.00 -48 12 22 12 -17
Acquisitions		 -0.33 - - - - 0.00 -17
Sale and/or Maturity of Investments		 - 0.00 36 57 48 12 0.00
Net Cash From Financing Activities		 0.00 187 0.00 0.51 2.88 0.00 267
Net Cash From Continuing Financing Activities		 0.00 187 0.00 0.51 2.88 0.00 267
Issuance of Common Equity		 0.00 88 0.00 0.51 2.88 0.00 267
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.01

Quarterly Cash Flow Statements for Damora Therapeutics, Inc. Common Stock

This table details how cash moves in and out of Damora Therapeutics, Inc. Common Stock's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.00 -1.89 -0.29 1.90 -3.65 -4.94 -2.44 -2.24 -2.62 250 275
Net Cash From Operating Activities		 -8.45 -11 -5.94 -4.10 -3.65 -4.94 -2.44 -2.24 -2.62 0.57 -21
Net Cash From Continuing Operating Activities		 -8.45 -11 -5.94 -4.10 -3.65 -4.94 -2.44 -2.24 -2.62 0.57 -20
Net Income / (Loss) Continuing Operations		 -8.14 -6.48 -5.48 -5.34 -3.88 -6.74 -2.53 -3.44 -3.13 -201 -28
Consolidated Net Income / (Loss)		 -8.14 -6.48 -5.48 -5.34 -3.88 -6.74 -2.53 -3.44 -3.13 -201 -28
Depreciation Expense		 0.21 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 -0.00 0.18 0.08 0.15 0.05 -0.06 0.00 0.00 0.01 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.47 1.03 1.36 0.90 0.77 2.21 0.21 0.17 0.18 184 3.13
Changes in Operating Assets and Liabilities, net		 -2.00 -6.24 -1.91 0.18 -0.59 -0.35 -0.12 1.02 0.33 17 4.21
Net Cash From Investing Activities		 8.29 9.58 5.65 6.00 - - 0.00 - - -17 0.00
Net Cash From Continuing Investing Activities		 8.29 9.58 5.65 6.00 - - 0.00 - - -17 0.00
Acquisitions		 - - - - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 12 9.50 5.65 6.00 - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.17 - 0.00 - - - 0.00 - - 267 296
Net Cash From Continuing Financing Activities		 0.17 - 0.00 - - - 0.00 - - 267 296
Issuance of Common Equity		 0.17 - 0.00 - - - 0.00 - - 267 296
Other Net Changes in Cash		 - - - - - - - - - - -0.05
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 0.00 - - 0.00

Annual Balance Sheets for Damora Therapeutics, Inc. Common Stock

This table presents Damora Therapeutics, Inc. Common Stock's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 57 172 122 73 38 17 261
Total Current Assets		 56 169 110 64 37 17 260
Cash & Equivalents		 11 164 63 33 21 14 258
Prepaid Expenses		 5.12 5.71 9.91 3.69 3.62 2.66 2.80
Plant, Property, & Equipment, net		 0.00 0.00 0.20 0.36 0.08 0.06 0.00
Total Noncurrent Assets		 0.53 2.30 12 8.92 1.38 0.24 0.10
Other Noncurrent Operating Assets		 0.53 2.30 2.86 3.09 1.38 0.24 0.10
Total Liabilities & Shareholders' Equity		 57 172 122 73 38 17 261
Total Liabilities		 8.14 6.11 4.99 11 5.90 1.30 20
Total Current Liabilities		 7.93 5.57 4.54 11 5.83 1.20 20
Accounts Payable		 3.33 2.85 1.53 3.35 1.70 0.38 18
Accrued Expenses		 4.60 2.72 3.01 7.76 4.13 0.82 2.40
Other Current Liabilities		 - - - - - - 0.00
Total Noncurrent Liabilities		 0.21 0.54 0.45 0.33 0.07 0.10 0.08
Other Noncurrent Operating Liabilities		 0.21 0.54 0.45 0.33 0.07 0.10 0.08
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -71 165 117 62 32 16 240
Total Preferred & Common Equity		 -71 165 117 62 32 16 240
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 416
Total Common Equity		 -71 165 117 62 32 16 -176
Common Stock		 0.83 269 274 280 288 292 311
Retained Earnings		 -70 -104 -156 -218 -256 -278 -487
Accumulated Other Comprehensive Income / (Loss)		 -2.45 0.67 -0.32 -0.24 0.38 0.10 0.80

Quarterly Balance Sheets for Damora Therapeutics, Inc. Common Stock

This table presents Damora Therapeutics, Inc. Common Stock's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 59 50 32 27 23 15 14 11 535
Total Current Assets		 55 47 31 25 21 15 13 9.79 535
Cash & Equivalents		 23 23 21 23 20 12 10 7.61 533
Prepaid Expenses		 3.24 2.88 3.37 2.31 1.50 2.98 2.82 2.18 2.51
Plant, Property, & Equipment, net		 0.33 0.13 0.07 0.07 0.06 0.05 0.05 0.04 0.00
Total Noncurrent Assets		 3.11 2.87 1.86 2.06 2.14 0.39 0.62 0.91 0.03
Other Noncurrent Operating Assets		 3.11 2.87 1.86 2.06 2.14 0.39 0.62 0.91 0.03
Total Liabilities & Shareholders' Equity		 59 50 32 27 23 15 14 11 535
Total Liabilities		 15 13 4.32 3.71 2.44 1.66 2.74 2.73 24
Total Current Liabilities		 15 13 4.32 3.71 2.44 1.55 2.63 2.62 24
Accounts Payable		 5.56 4.48 1.67 0.72 0.50 0.35 0.76 0.52 13
Accrued Expenses		 9.34 8.08 2.65 2.99 1.94 1.20 1.87 2.10 6.00
Other Current Liabilities		 - - - - - - - - 4.98
Total Noncurrent Liabilities		 0.21 0.11 0.00 0.00 0.00 0.11 0.11 0.11 0.03
Other Noncurrent Operating Liabilities		 0.21 0.11 0.00 0.00 0.00 0.11 0.11 0.11 0.03
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 44 37 28 24 21 14 11 8.01 512
Total Preferred & Common Equity		 44 37 28 24 21 14 11 8.01 512
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 1.36 - - 132
Total Common Equity		 44 37 28 24 21 12 11 8.01 379
Common Stock		 285 287 289 290 291 292 292 292 894
Retained Earnings		 -241 -250 -262 -267 -271 -280 -283 -287 -515
Accumulated Other Comprehensive Income / (Loss)		 -0.14 0.05 0.33 0.20 0.67 0.30 0.81 0.82 0.75

Annual Metrics And Ratios for Damora Therapeutics, Inc. Common Stock

This table displays calculated financial ratios and metrics derived from Damora Therapeutics, Inc. Common Stock's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 25,260,816.00 25,261,832.00 25,581,029.00 27,112,697.00 1,316,989.00 1,327,212.00
DEI Adjusted Shares Outstanding		 0.00 1,010,433.00 1,010,473.00 1,023,241.00 1,084,508.00 1,316,989.00 1,327,212.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -34.48 -52.20 -60.15 -34.79 -16.28 -158.11
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 27 -24 -37 -43 -28 -16 -148
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -86.40% -98.43% -61.41%
Earnings before Interest and Taxes (EBIT)		 41 -35 -52 -62 -40 -22 -211
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 42 -35 -50 -62 -40 -22 -211
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 12 -43 -31 -31 -18 -129
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 37 1.91 7.98 -4.30 -0.82 1.66 -17
Increase / (Decrease) in Invested Capital		 0.00 -35 6.08 -12 3.48 2.48 -19
Book Value per Share		 ($273.68) $6.55 $4.64 $2.41 $1.19 $12.02 ($131.50)
Tangible Book Value per Share		 ($273.68) $6.55 $4.64 $2.41 $1.19 $12.02 ($131.50)
Total Capital		 48 165 117 62 32 16 240
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -11 -164 -109 -66 -33 -14 -258
Capital Expenditures (CapEx)		 0.00 0.00 0.22 0.20 -0.08 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 37 0.15 5.37 -7.42 -2.21 1.47 -17
Debt-free Net Working Capital (DFNWC)		 48 164 106 53 31 16 240
Net Working Capital (NWC)		 48 164 106 53 31 16 240
Net Nonoperating Expense (NNE)		 64 11 15 19 10 5.86 62
Net Nonoperating Obligations (NNO)		 -11 -164 -109 -66 -33 -14 -258
Total Depreciation and Amortization (D&A)		 0.11 0.19 1.51 0.61 0.40 0.25 0.03
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($7.62) ($2.05) ($2.43) ($36.00) ($18.53) $3.98
Adjusted Weighted Average Basic Shares Outstanding		 0.00 25.26M 25.26M 25.41M 1.06M 1.16M 1.36M
Adjusted Diluted Earnings per Share		 $0.00 ($7.62) ($2.05) ($2.43) ($36.00) ($18.53) $3.98
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 25.26M 25.26M 25.41M 1.06M 1.16M 1.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($7.62) ($2.05) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 4.57M 25.26M 25.67M 1.08M 1.32M 60.30M
Normalized Net Operating Profit after Tax (NOPAT)		 27 -24 -37 -43 -26 -15 -148
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Damora Therapeutics, Inc. Common Stock

This table displays calculated financial ratios and metrics derived from Damora Therapeutics, Inc. Common Stock's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 27,112,697.00 27,112,697.00 27,112,697.00 27,112,697.00 27,130,196.00 1,316,989.00 1,322,359.00 1,322,359.00 1,324,560.00 1,327,212.00 60,303,212.00
DEI Adjusted Shares Outstanding		 1,084,508.00 1,084,508.00 1,084,508.00 1,084,508.00 1,085,208.00 1,316,989.00 1,322,359.00 1,322,359.00 1,324,560.00 1,327,212.00 60,303,212.00
DEI Earnings Per Adjusted Shares Outstanding		 -7.33 -5.66 -5.10 -5.04 -3.15 -5.33 -1.76 -2.21 -2.35 -151.79 -0.46
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 39.30% 54.46% 57.99% 52.17% 52.83% -6.35% 54.02% 35.07% 20.12% - -1,086.21%
EBIT Growth		 38.29% 52.52% 57.30% 50.75% 53.28% -2.38% 54.57% 36.78% 21.06% - -1,082.76%
NOPAT Growth		 36.99% 50.68% 57.45% 50.02% 55.26% -6.46% 54.73% 38.66% 17.81% - -1,085.49%
Net Income Growth		 40.74% 53.98% 57.85% 50.32% 52.27% -4.11% 53.75% 35.61% 19.32% - -996.84%
EPS Growth		 40.74% 53.98% 57.85% 50.32% 54.80% -9.34% 61.98% 47.15% 30.38% - 67.71%
Operating Cash Flow Growth		 14.15% -0.23% 35.01% 47.76% 56.81% 56.98% 58.91% 45.44% 28.35% - -744.53%
Free Cash Flow Firm Growth		 45.07% -389.15% -294.79% -5,424.29% -347.90% 8.65% 78.11% 81.53% 87.40% - 157.60%
Invested Capital Growth		 -113.31% 80.94% 114.36% 108.62% 118.50% 301.95% 79.15% 2.20% -68.10% - -1,303.16%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 24.90% 21.30% 14.57% 5.28% 25.94% -77.46% 63.06% -33.77% 8.89% - 84.73%
EBIT Q/Q Growth		 23.04% 20.84% 15.86% 3.92% 26.99% -73.47% 62.66% -33.70% 8.84% - 84.72%
NOPAT Q/Q Growth		 23.08% 22.28% 13.94% 2.86% 31.15% -84.95% 63.40% -31.63% 7.75% - 84.72%
Net Income Q/Q Growth		 24.27% 20.42% 15.41% 2.54% 27.26% -73.60% 62.42% -35.69% 8.84% - 86.16%
EPS Q/Q Growth		 24.27% 20.42% 15.41% 2.54% 31.10% -86.43% 69.62% -35.42% 9.23% - 99.58%
Operating Cash Flow Q/Q Growth		 -7.71% -35.72% 48.27% 30.93% 10.95% -35.20% 50.59% 8.28% -16.94% - -3,739.22%
Free Cash Flow Firm Q/Q Growth		 -914.85% -239.97% -45.78% -9.84% 17.72% 30.66% 65.07% 7.33% 43.87% - 101.23%
Invested Capital Q/Q Growth		 19.33% 87.93% 220.49% -26.52% 73.14% 31.74% 6.88% -58.08% -45.96% - -23.50%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.79% 100.18% 99.88% 100.08% 100.12% 100.00% - 100.15%
Interest Burden Percent		 94.51% 95.01% 95.52% 96.13% 96.37% 96.73% 97.16% 98.56% 98.68% - 90.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -83.45% -81.52% -78.56% -75.57% -72.61% -89.03% -88.35% -96.08% -109.49% - -89.50%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -3,074.27% -3,822.37% -1,856.27% -1,090.46% -1,027.16% -1,619.81% -1,271.24% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -83.45% -81.52% -78.56% -75.57% -72.61% -86.51% -85.48% -96.08% -109.49% - -66.71%
Return on Equity Simple (ROE_SIMPLE)		 -122.90% 0.00% -109.49% 0.00% 0.00% 0.00% -134.91% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.01 -4.67 -4.02 -3.90 -2.69 -4.97 -1.82 -2.39 -2.21 -141 -22
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.54% -3.64% -3.46% -3.83% -3.74% -7.48% -3.65% -6.30% -6.77% - -2.28%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.44% -14.27% -16.55% -12.84% -31.40% -13.27% -21.86% -27.59% -58.74% -4.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.61 -6.82 -5.73 -5.51 -4.02 -6.98 -2.61 -3.48 -3.18 -202 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.40 -6.61 -5.65 -5.35 -3.96 -7.03 -2.60 -3.47 -3.17 -202 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.52 0.60 0.75 0.55 0.63 0.42 0.33 0.41 0.62 - 4.12
Price to Tangible Book Value (P/TBV)		 0.52 0.60 0.75 0.55 0.63 0.42 0.33 0.41 0.62 - 4.12
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.09 -1.05 -1.08 -1.11 -1.10 -0.98 -0.93 -0.96 -0.94 - -1.04
Leverage Ratio		 1.20 1.18 1.24 1.28 1.26 1.15 1.14 1.19 1.18 - 1.05
Compound Leverage Factor		 1.13 1.13 1.18 1.23 1.21 1.11 1.11 1.17 1.16 - 0.94
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 8.59% 9.92% 0.00% 0.00% - 25.89%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 91.41% 90.08% 100.00% 100.00% - 74.11%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -5.80 -7.01 -7.95 -11.33 -12.58 -20.10 -23.55 -27.93 -36.47 - 38.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 2.82% 3.25% 0.00% 0.00% - 25.47%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.75 6.31 7.07 6.79 8.68 14.07 9.62 4.96 3.73 - 22.48
Quick Ratio		 3.52 5.69 6.29 6.16 8.06 11.84 7.70 3.88 2.90 - 22.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.40 -8.15 -12 -13 -11 -7.45 -2.60 -2.41 -1.35 -122 1.50
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.80 -0.82 0.99 0.73 1.26 1.66 1.77 0.74 0.40 -17 -21
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -3.61 3.48 7.87 9.15 8.05 2.48 0.78 0.02 -0.86 -19 -23
Enterprise Value (EV)		 -25 -14 -6.02 -10 -6.49 -6.69 -6.48 -5.70 -2.68 - 1,161
Market Capitalization		 20 20 21 13 13 6.12 4.10 4.51 4.93 - 1,562
Book Value per Share		 $1.38 $1.19 $1.04 $0.87 $0.77 $12.02 $9.34 $8.28 $6.05 ($131.50) $6.29
Tangible Book Value per Share		 $1.38 $1.19 $1.04 $0.87 $0.77 $12.02 $9.34 $8.28 $6.05 ($131.50) $6.29
Total Capital		 37 32 28 24 21 16 14 11 8.01 240 512
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -44 -33 -27 -23 -20 -14 -12 -10 -7.61 -258 -533
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.68 -2.21 -0.95 -1.40 -0.94 1.47 1.43 0.19 -0.44 -17 -21
Debt-free Net Working Capital (DFNWC)		 34 31 26 21 19 16 13 10 7.16 240 512
Net Working Capital (NWC)		 34 31 26 21 19 16 13 10 7.16 240 512
Net Nonoperating Expense (NNE)		 2.13 1.81 1.46 1.43 1.20 1.77 0.71 1.04 0.92 60 6.22
Net Nonoperating Obligations (NNO)		 -44 -33 -27 -23 -20 -14 -12 -10 -7.61 -258 -533
Total Depreciation and Amortization (D&A)		 0.21 0.20 0.09 0.16 0.06 -0.05 0.01 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.50) ($144.50) ($5.00) ($5.00) ($3.39) ($6.07) ($1.92) ($2.60) ($2.36) ($147.81) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 1.08M 42.52K 1.08M 1.08M 1.14M 1.16M 1.32M 1.32M 1.33M 1.36M 34.30M
Adjusted Diluted Earnings per Share		 ($7.50) ($144.50) ($5.00) ($5.00) ($3.39) ($6.07) ($1.92) ($2.60) ($2.36) ($147.81) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 1.08M 42.52K 1.08M 1.08M 1.14M 1.16M 1.32M 1.32M 1.33M 1.36M 34.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($144.50) $0.00 $0.00 $0.00 ($6.07) $0.00 $0.00 $0.00 ($147.81) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.08M 1.08M 1.08M 1.09M 1.32M 1.32M 1.32M 1.32M 1.33M 60.30M 61.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.10 -4.67 -4.02 -3.23 -2.69 -4.97 -1.82 -2.39 -2.21 -141 -22
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, year-over-year look at DMRA’s latest quarterly filings. The data shows a biotech company primarily funded by equity raises, with no reported revenue in the periods shown, and ongoing net losses. The most notable recent development is a large equity issuance in Q4 2025 that substantially boosted cash from financing activities.

  • Issuance of Common Equity in Q4 2025: 266,844,000 USD. This represents a large equity fundraising event that significantly increased cash resources and liquidity.
  • Net Cash From Continuing Financing Activities in Q4 2025: +266,844,000 USD. The financing activity itself was a major liquidity driver.
  • Net Change in Cash & Equivalents in Q4 2025: +250,036,000 USD. The quarter benefited from the equity raise, sharply increasing cash on hand.
  • Non-Cash Adjustments To Reconcile Net Income in Q4 2025: +184,157,000 USD. These one-time, non-cash adjustments helped reconcile reported earnings with cash flow, contributing to the CFO presentation.
  • Total Revenue across the latest four quarters remains 0 USD, indicating no product revenue in periods shown.
  • Weighted average basic/diluted shares outstanding rose to about 60.3 million in Q4 2025, contributing to a very large negative earnings-per-share figure (EPS of -147.81). This highlights substantial dilution from the equity raise.
  • Operating expenses remain high relative to revenue, with R&D around 197.6 million USD and SG&A around 4.07 million USD in Q4 2025, typical of biotech pre-revenue phases but a headwind for profitability.
  • Net income / loss attributable to common shareholders in Q4 2025: -201.46 million USD. This underscores ongoing material losses despite the large financing inflow.
  • Net cash from continuing operating activities has been negative in multiple quarters (e.g., Q3 2025: -2.62 million; Q2 2025: -2.24 million; Q1 2025: -2.44 million), signaling continued cash burn from core operations even as financing inflows occur.
  • Deficits shown in retained earnings (e.g., Q3 2025: -283.49 million; Q4 2025 disclosures reflect ongoing, substantial accumulated losses), indicating a challenging path to profitability without meaningful top-line growth.
05/23/26 09:42 AM ETAI Generated. May Contain Errors.

Damora Therapeutics, Inc. Common Stock Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Damora Therapeutics, Inc. Common Stock's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Damora Therapeutics, Inc. Common Stock's net income appears to be on an upward trend, with a most recent value of -$209.84 million in 2025, rising from -$36.51 million in 2019. The previous period was -$21.44 million in 2024. See Damora Therapeutics, Inc. Common Stock's forecast for analyst expectations on what's next for the company.

Damora Therapeutics, Inc. Common Stock's total operating income in 2025 was -$210.87 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $210.87 million

Over the last 6 years, Damora Therapeutics, Inc. Common Stock's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Damora Therapeutics, Inc. Common Stock's total liabilities were at $20.15 million at the end of 2025, a 1,448.6% increase from 2024, and a 147.6% increase since 2019.

In the past 6 years, Damora Therapeutics, Inc. Common Stock's cash and equivalents has ranged from $11.29 million in 2019 to $257.62 million in 2025, and is currently $257.62 million as of their latest financial filing in 2025.

Over the last 6 years, Damora Therapeutics, Inc. Common Stock's book value per share changed from -273.68 in 2019 to -131.50 in 2025, a change of -52.0%.


Related Companies

Financial statements for NASDAQ:DMRA last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel